blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2663297

EP2663297 - METHODS AND COMPOSITIONS FOR PROTECTION OF CELLS AND TISSUES FROM COMPUTED TOMOGRAPHY RADIATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.08.2020
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  20.09.2019
FormerGrant of patent is intended
Status updated on  25.04.2019
FormerExamination is in progress
Status updated on  30.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
The University of Chicago
5801 South Ellis Avenue
Chicago, IL 60637 / US
[2013/47]
Inventor(s)01 / GRDINA, David, J.
94 N. Stauffer Dr.
Naperville, IL 60540 / US
 [2013/47]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2019/43]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2013/47]Bentham, Andrew
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date11771290.116.09.2011
[2019/43]
WO2011US51946
Priority number, dateUS20100383592P16.09.2010         Original published format: US 383592 P
[2013/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012037466
Date:22.03.2012
Language:EN
[2012/12]
Type: A2 Application without search report 
No.:EP2663297
Date:20.11.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2012 takes the place of the publication of the European patent application.
[2013/47]
Type: B1 Patent specification 
No.:EP2663297
Date:23.10.2019
Language:EN
[2019/43]
Search report(s)International search report - published on:EP10.05.2012
ClassificationIPC:A61K31/13, A61P39/06, A61K31/661
[2013/47]
CPC:
A61K31/661 (EP,US); A61B6/032 (US); A61B6/508 (EP,US);
A61K31/132 (EP,US); A61K31/145 (EP,US); A61K31/355 (EP,US);
A61K33/04 (EP,US); A61K45/06 (EP,US); A61K49/0008 (US);
A61P39/06 (EP) (-)
C-Set:
A61K31/132, A61K2300/00 (EP,US);
A61K31/355, A61K2300/00 (US,EP);
A61K31/661, A61K2300/00 (US,EP);
A61K33/04, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/47]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUM SCHUTZ VON ZELLEN UND GEWEBE VON COMPUTERTOMOGRAFIESTRAHLUNG[2013/47]
English:METHODS AND COMPOSITIONS FOR PROTECTION OF CELLS AND TISSUES FROM COMPUTED TOMOGRAPHY RADIATION[2013/47]
French:MÉTHODES ET COMPOSITIONS UTILISÉES POUR PROTÉGER LES CELLULES ET LES TISSUS DES RAYONNEMENTS ÉMIS LORS D'UNE TOMODENSITOMÉTRIE[2013/47]
Entry into regional phase07.06.2013National basic fee paid 
07.06.2013Designation fee(s) paid 
07.06.2013Examination fee paid 
Examination proceduredeletedDeletion: Application deemed to be withdrawn, date of legal effect  [2013/47]
24.05.2013Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time  [2013/47]
07.06.2013Examination requested  [2013/47]
02.05.2014Amendment by applicant (claims and/or description)
24.06.2014Despatch of a communication from the examining division (Time limit: M04)
11.08.2014Reply to a communication from the examining division
04.12.2014Despatch of a communication from the examining division (Time limit: M04)
14.04.2015Reply to a communication from the examining division
08.02.2016Despatch of a communication from the examining division (Time limit: M04)
27.05.2016Reply to a communication from the examining division
20.12.2016Despatch of a communication from the examining division (Time limit: M02)
16.02.2017Reply to a communication from the examining division
10.10.2017Despatch of a communication from the examining division (Time limit: M02)
19.12.2017Reply to a communication from the examining division
12.03.2018Despatch of a communication from the examining division (Time limit: M04)
10.07.2018Reply to a communication from the examining division
26.04.2019Communication of intention to grant the patent
23.08.2019Fee for grant paid
23.08.2019Fee for publishing/printing paid
23.08.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19194979.1  / EP3632419
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.06.2014
Opposition(s)24.07.2020No opposition filed within time limit [2020/40]
Request for further processing for:07.06.2013Request for further processing filed
07.06.2013Full payment received (date of receipt of payment)
Request granted
22.10.2013Decision despatched
The application is deemed to be withdrawn due to non-payment of the filing fee
07.06.2013Request for further processing filed
07.06.2013Full payment received (date of receipt of payment)
Request granted
22.10.2013Decision despatched
The application is deemed to be withdrawn due to non-payment of the examination fee
07.06.2013Request for further processing filed
07.06.2013Full payment received (date of receipt of payment)
Request granted
22.10.2013Decision despatched
07.06.2013Request for further processing filed
07.06.2013Full payment received (date of receipt of payment)
Request granted
22.10.2013Decision despatched
The application is deemed to be withdrawn due to non-payment of designation fees
TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL
07.06.2013Request for further processing filed
07.06.2013Full payment received (date of receipt of payment)
Request granted
22.10.2013Decision despatched
Fees paidRenewal fee
12.09.2013Renewal fee patent year 03
12.09.2014Renewal fee patent year 04
11.09.2015Renewal fee patent year 05
13.09.2016Renewal fee patent year 06
12.09.2017Renewal fee patent year 07
11.09.2018Renewal fee patent year 08
13.09.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL23.10.2019
AT23.10.2019
CY23.10.2019
CZ23.10.2019
DK23.10.2019
EE23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
MC23.10.2019
MK23.10.2019
MT23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
SI23.10.2019
SK23.10.2019
SM23.10.2019
BG23.01.2020
NO23.01.2020
IS23.02.2020
PT24.02.2020
[2022/32]
Former [2022/27]AL23.10.2019
AT23.10.2019
CY23.10.2019
CZ23.10.2019
DK23.10.2019
EE23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
MC23.10.2019
MT23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
SI23.10.2019
SK23.10.2019
SM23.10.2019
BG23.01.2020
NO23.01.2020
IS23.02.2020
PT24.02.2020
Former [2021/23]AL23.10.2019
AT23.10.2019
CZ23.10.2019
DK23.10.2019
EE23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
MC23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
SI23.10.2019
SK23.10.2019
SM23.10.2019
BG23.01.2020
NO23.01.2020
IS23.02.2020
PT24.02.2020
Former [2020/51]AL23.10.2019
AT23.10.2019
CZ23.10.2019
DK23.10.2019
EE23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
SI23.10.2019
SK23.10.2019
SM23.10.2019
BG23.01.2020
NO23.01.2020
IS23.02.2020
PT24.02.2020
Former [2020/37]AL23.10.2019
CZ23.10.2019
DK23.10.2019
EE23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
SK23.10.2019
SM23.10.2019
BG23.01.2020
NO23.01.2020
IS23.02.2020
PT24.02.2020
Former [2020/36]AL23.10.2019
CZ23.10.2019
DK23.10.2019
EE23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
IS23.02.2020
PT24.02.2020
Former [2020/35]AL23.10.2019
CZ23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
RO23.10.2019
RS23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
IS24.02.2020
PT24.02.2020
Former [2020/32]AL23.10.2019
FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
RS23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
IS24.02.2020
PT24.02.2020
Former [2020/26]FI23.10.2019
HR23.10.2019
LT23.10.2019
LV23.10.2019
RS23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
IS24.02.2020
PT24.02.2020
Former [2020/24]FI23.10.2019
LT23.10.2019
LV23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
IS24.02.2020
PT24.02.2020
Former [2020/23]FI23.10.2019
LT23.10.2019
LV23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
PT24.02.2020
Former [2020/22]FI23.10.2019
LT23.10.2019
SE23.10.2019
BG23.01.2020
NO23.01.2020
PT24.02.2020
Former [2020/21]NO23.01.2020
Cited inInternational search[Y]WO9507700  (ARCH DEV CORP [US]) [Y] 1-32 * See page 1, lines 1-6, figures, page 12, 3rd paragraph, pages 14-18: phosphorothioates, and in particular amifostine (WR 2721) and WR 2065 protect against radiation damage. Hprt mutations are also prevented (see page 17) *;
 [Y]  - HUANG BINGSHENG ET AL, "Whole-body PET/CT scanning: estimation of radiation dose and cancer risk.", RADIOLOGY, (200904), vol. 251, no. 1, ISSN 1527-1315, pages 166 - 174, XP002670473 [Y] 1-32 * See page 166, "purpose", "results" and "conclusion", page 173, left hand column and table 5: PET / Computer tomography is accompanied by substantial radiation dose and cancer risk *

DOI:   http://dx.doi.org/10.1148/radiol.2511081300
 [Y]  - BENZ MARK G ET AL, "Reduction of cancer risk associated with pediatric computed tomography by the development of new technologies.", PEDIATRICS, (200407), vol. 114, no. 1, ISSN 1098-4275, pages 205 - 209, XP002670474 [Y] 1-32 * See page 205 left hand column, page 207 "conclusions" and page 208 left hand column: risks associated with pediatric computer tomography and strategies for their reduction *

DOI:   http://dx.doi.org/10.1542/peds.114.1.205
 [Y]  - HOSSEINIMEHR SEYED JALAL, "Potential utility of radioprotective agents in the practice of nuclear medicine.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, (200912), vol. 24, no. 6, ISSN 1557-8852, pages 723 - 731, XP002670475 [Y] 1-32 * See abstract and page 723: radioprotective agents reduce chromosomal aberration caused by gamma and beta rays produced by radiopharmaceuticals used for imaging purposes. See page 725, left hand column, reference to radiation used in PET tomography See page 728, right hand column: amifostine (WR 2721) protects from DNA damage caused by radiotherapy and radiology *

DOI:   http://dx.doi.org/10.1089/CBR.2009.0635
 [XY]  - MILLER G G ET AL, "Computed tomographic assessment of radiation induced damage in the lung of normal and WR 2721 protected LAF1 mice", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 12, no. 11, ISSN 0360-3016, (19861101), pages 1971 - 1975, (19861101), XP026843287 [X] 27 * See abstract, results and discussion: amifostine (WR 2721) reduces lung tissue damage (pneumonitis and fibrosis) induced by CT * [Y] 1-32
 [Y]  - DZIEGIELEWSKI JAROSLAW ET AL, "WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.", FREE RADICAL BIOLOGY & MEDICINE, (20081215), vol. 45, no. 12, ISSN 0891-5849, pages 1674 - 1681, XP002670476 [Y] 1-32 * See abstract, page 1675 left hand column second paragraph, page 1676 ff "results", figures: WR 1065 the active metabolite of amifostine protects from immediate radiation damage, as well as delayed mutagenic effects measured by hyperrecombination and mutation in GTP construct and micronucleous formation in surviving cells. WR 1065 increases MnSOD levels. See pages 1678-1680 "discussion": WR 1065 protects from radiation-induced genomic instability and risk of cancerogenesis *

DOI:   http://dx.doi.org/10.1016/J.FREERADBIOMED.2008.09.004
 [Y]  - HOOKER ANTONY M ET AL, "Low doses of amifostine protect from chromosomal inversions in spleen in vivo when administered after an occupationally relevant X-radiation dose", INTERNATIONAL JOURNAL OF LOW RADIATION, (2009), vol. 6, no. 1, pages 43 - 56, XP009156936 [Y] 1-32 * See abstract, page 46 and page 50: amifostine is the only FDA approved radioprotective compound. It protects from radiation mutagenesis, inducing the NFkB pathway mediated by MnSOD and in particular it protects from chromosomal inversion. Furthermore, (see page 50) its metabolite WR 1065 protects from Hprt mutations *

DOI:   http://dx.doi.org/10.1504/IJLR.2009.026239
 [Y]  - DZIEGIELEWSKI JAROSLAW ET AL, "Amifostine metabolite WR-1065 disrupts homologous recombination in mammalian cells.", RADIATION RESEARCH, (201002), vol. 173, no. 2, ISSN 1938-5404, pages 175 - 183, XP002670477 [Y] 1-32 * See abstract: WR 1065 decreases homologous recombination in response to DNA radiation damage preventing genomic instability *

DOI:   http://dx.doi.org/10.1667/RR1982.1
Examination   - Natsuhisa Oka ET AL, "Stereocontrolled Synthesis of Oligoribonucleoside Phosphorothioates by an Oxazaphospholidine Approach", Organic Letters, (20090219), vol. 11, no. 4, doi:10.1021/ol802910k, ISSN 1523-7060, pages 967 - 970, XP055179581

DOI:   http://dx.doi.org/10.1021/ol802910k
by applicantUS5488042
 US5567686
 US5869338
 US5891856
 US6984619
    - TUCKER, LUCKINBILL, RADIAL RES., (2011), vol. 175, no. 5, pages 631 - 7
    - BHATTI ET AL., RADIAL. ENVIRON. BIOPHYS., (2010), vol. 49, no. 4, pages 685 - 692
    - SIGURDSON ET AL., CANCER RES., (2008), vol. 68, no. 21, pages 8825 - 8831
    - KIM ET AL., CANCER RES., (2006), vol. 66, pages 10377 - 10383
    - MURLEY ET AL., RADIAT. RES., (2011), vol. 175, pages 57 - 65
    - KATAOKA ET AL., RADIAT. RES., (2007), vol. 168, pages 106 - 114
    - ROTHKAMM ET AL., RADIOLOGY, (2007), vol. 242, pages 244 - 251
    - KUMAR ET AL., RADIAT RES., (2006), vol. 165, no. 1, pages 43 - 50
    - JONES ET AL., RADIAT RES., (2002), vol. 158, no. 4, pages 424 - 42
    - PAMUJULA, S., J. PHARMACY PHARMACOL., (2004), vol. 56, pages 1119 - 1125
    - LAMPERTI ET AL., RADIATION RES., (1990), vol. 124, pages 194 - 200
    - SRINIVASAN ET AL., INT. J. RADIAT. BIOL., (2002), vol. 78, pages 535 - 543
    - J.S. MURLEY ET AL., RADIAT. RES., (2011), vol. 175, pages 57 - 65
    - J.S. MURLEY ET AL., RADIAT. RES., (2008), vol. 169, pages 495 - 505
    - BHATTI ET AL., RADIAT. ENVIRON. BIOPHYS., (2010), vol. 49, no. 4, pages 685 - 692
    - BRENNER ET AL., AM. J: ROENTGENOL., (2001), vol. 176, no. 2, pages 289 - 96
    - GIAMBARRESI, JACOBS, Military Radiobiology, ACADEMIC PRESS, (1987), pages 265 - 301
    - GRDINA ET AL., CARCINOGENESIS, (1995), vol. 16, no. 4, pages 767 - 774
    - HUANG ET AL., MOLEC. CELL. BIOL., (2004), vol. 24, no. 11, pages 5060 - 5068
    - JONES ET AL., RADIAT. RES., (2002), vol. 158, no. 4, pages 424 - 42
    - KATAOKA ET AL., RADIAT. RES., (2007), vol. 168, pages 106 - 11
    - KUMAR ET AL., RADIAT. RES., (2006), vol. 165, no. 1, pages 43 - 50
    - LAMPERTI ET AL., RADIAT. RES., (1990), vol. 124, pages 194 - 200
    - LI ET AL., PROSTATE, (1998), vol. 35, pages 221 - 233
    - LIMOLI ET AL., CANCER RES., (1997), vol. 57, no. 18, pages 4048 - 4056
    - MARDER, MORGAN, MOL. CELL. BIOL., (1993), vol. 13, no. 11, pages 6667 - 6677
    - MORGAN, RADIAT. RES., (2003), vol. 159, no. 5, pages 567 - 580
    - MORGAN, RADIAT. RES., (2003), vol. 159, no. 5, pages 581 - 596
    - MURLEY ET AL., RADIAL. RES., (2002), vol. 158, no. 1, pages 101 - 109
    - MURLEY ET AL., RADIAT. RES., (2004), vol. 162, pages 536 - 546
    - MURLEY ET AL., FREE RADICAL. BIOL. MED., (2006), vol. 40, pages 1004 - 1016
    - MURLEY ET AL., RADIAT. RES., (2007), vol. 167, pages 465 - 474
    - MURLEY ET AL., RADIAL. RES., (2008), vol. 169, pages 495 - 505
    - NICKOLOFF, Encyclopedia of Cancer, ELSEVIER SCIENCE, (2002), vol. 4, pages 49 - 59
    - OBERLEY, SPITZ, Methods in Enzymology, ACADEMIC PRESS, (1984), vol. 105, pages 457 - 469
    - PAMUJULA, S. ET AL., J. PHARMACY PHARMACOL., (2004), vol. 56, pages 1119 - 25
    - ROTHKAMM ET AL., RADIOLOGY, (2007), vol. 242, pages 244 - 51
    - SEMELKA ET AL., J. MAGN. RESON. IMAGING, (2007), vol. 25, no. 5, pages 900 - 9
    - SMITH ET AL., HEALTH PHYS., (2003), vol. 85, no. 1, pages 23 - 29
    - SWEENEY, RADIOL. TECHNOL., (1979), vol. 51, no. 3, pages 321 - 7
    - TUCKER, LUCKINBILL, RADIAT RES., (2011), vol. 175, no. 5, pages 631 - 7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.